Sesen Bio Receives Complete Response Letter from FDA for Vicineum (oportuzumab monatox-qqrs)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 13, 2021-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it received a...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news